Company news

Altimmune, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

May 3, 2023

Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B

April 10, 2023

Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

March 26, 2023

Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial

March 20, 2023

Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

February 27, 2023

Altimmune Appoints Raymond Jordt as Chief Business Officer

January 3, 2023

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023

January 3, 2023

Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

December 19, 2022

Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update

November 9, 2022

Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

September 27, 2022

Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

September 13, 2022

Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update

August 10, 2022

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022

June 16, 2022

Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022

May 30, 2022

Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update

May 11, 2022

Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12

May 4, 2022

Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity

March 31, 2022

Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

March 14, 2022

Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

March 7, 2022

Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity

January 30, 2022

Altimmune Appoints Richard Eisenstadt as Chief Financial Officer

December 12, 2021

Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

November 8, 2021

Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021

November 2, 2021

Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease

October 3, 2021

Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers

September 27, 2021

Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021

September 26, 2021

Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update

August 9, 2021

Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021

August 3, 2021

Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial

June 28, 2021

Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers

June 15, 2021

Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update

May 16, 2021

Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021

May 10, 2021

Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose

May 9, 2021

Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™

March 31, 2021

Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine Candidate

March 21, 2021

Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza

March 11, 2021

Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate

February 24, 2021

Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update

February 24, 2021

Altimmune To Announce Year End 2020 Financial Results on February 25, 2021

February 21, 2021

Altimmune Announces FDA Clearance of AdCOVID™ IND Application

February 16, 2021

Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B

December 29, 2020

Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial

December 22, 2020

Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH

December 7, 2020

Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December

November 24, 2020

Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal Vaccine Candidate for COVID-19

November 9, 2020

Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update

November 8, 2020

Altimmune to Announce Third Quarter 2020 Financial Results on November 10

November 2, 2020

Altimmune and UAB Announce Publication of Compelling Pre-clinical Data for AdCOVID™ Intranasal COVID-19 Vaccine Candidate

October 11, 2020

Altimmune Announces Successful Completion of Multiple Dose Toxicity and Toxicokinetic Studies of ALT-801, a GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH

August 31, 2020

Altimmune Announces Data Presentation on ALT-801, its Balanced and Long-Acting GLP-1/Glucagon Receptor Dual Agonist for NASH, at the Digital International Liver Congress™ 2020

August 25, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 27 decks. Every deck is listed under its year.